THC is fat-soluble and accumulates in adipose tissue — here is what that means for detection windows, metabolism, and why exercise can complicate a drug test.
Delta-9-tetrahydrocannabinol (THC) is a highly lipophilic molecule — it has a strong affinity for fats and oils while exhibiting very low water solubility. This physicochemical property fundamentally dictates how cannabis is distributed, stored and eliminated by the human body. Unlike water-soluble compounds such as ethanol, which are rapidly diluted throughout total body water and metabolised at a relatively predictable rate, THC partitions preferentially into fat-rich tissues throughout the body.
When cannabis is inhaled or ingested, THC enters the bloodstream rapidly and is distributed first to highly vascularised, lipid-rich organs including the brain, heart, liver and lungs. This initial distribution phase accounts for the rapid onset of psychoactive effects. Over the subsequent hours, THC progressively redistributes to peripheral fat stores — subcutaneous and visceral adipose tissue, as well as lipid-rich cell membranes throughout the body.
The volume of distribution (Vd) of THC is estimated at 10 L/kg, which is extraordinarily high compared to most pharmacological compounds and reflects the extent of its tissue partitioning. This massive distribution volume means that only a small fraction of total THC in the body is present in the blood at any given time — a critical point for understanding why blood tests can underestimate recent consumption in chronic users while still detecting use days after the last dose.
The biological half-life of THC in adipose tissue ranges from several days to weeks, depending on the individual’s body composition. This is fundamentally different from the acute blood half-life of approximately 1–3 hours in casual users, which reflects only the first distribution phase. In chronic heavy users, THC has been detected in blood and urine weeks after the last consumption event due to slow release from fat depots.
The liver is the primary site of THC metabolism. After distribution through the body, THC is returned to the liver where it undergoes extensive first-pass and secondary hepatic metabolism through cytochrome P450 enzymes, primarily CYP2C9 and CYP3A4. This metabolic pathway converts THC through a series of oxidation reactions into increasingly polar (water-soluble) metabolites that can then be excreted in urine and faeces.
The first metabolite produced is 11-hydroxy-THC (11-OH-THC), which is notably psychoactive — in fact, studies suggest it may be more potent than delta-9-THC itself in crossing the blood-brain barrier. This is one reason edibles produce a qualitatively different, often more intense and prolonged effect compared to inhalation: when cannabis is consumed orally and processed through the gut and liver before reaching systemic circulation, the proportion of 11-OH-THC is substantially higher.
11-OH-THC is further oxidised to 11-nor-9-carboxy-THC, universally abbreviated as THC-COOH or carboxy-THC. This compound is pharmacologically inactive — it produces no psychoactive effects — but it is the primary metabolite targeted by urine drug immunoassay tests. THC-COOH is highly lipophilic and undergoes enterohepatic recirculation, meaning it cycles between the liver and gut, which prolongs its elimination.
THC-COOH conjugated with glucuronic acid (THC-COOH glucuronide) is the form eventually excreted in urine. This conjugation step occurs in the liver and increases water solubility enough for renal excretion. However, the process is slow, and stored THC-COOH in adipose tissue continues feeding back into hepatic metabolism long after the last consumption event.
Faecal elimination accounts for approximately 65% of total THC metabolite excretion, with urinary excretion accounting for around 20–35%. This explains why urinary drug test results can persist long after the subject has ceased consuming — the fat-tissue reservoir continues slowly releasing THC into the blood for hepatic conversion and urinary excretion for weeks.
The critical practical implication of THC’s lipophilicity is the relationship between body fat percentage and detection window duration. Individuals with a higher proportion of adipose tissue have a larger biological reservoir for THC storage. They accumulate more THC per consumed unit, release it more slowly back into the bloodstream, and consequently show detectable levels in drug tests for substantially longer periods.
Research comparing detection windows between subjects of different body mass indices (BMIs) has consistently shown that heavier individuals with higher body fat percentages test positive for longer after equivalent cannabis exposure. A lean individual (12% body fat) who consumes cannabis daily for one month may test clean within 2–3 weeks of stopping; an individual with 30% body fat under the same protocol may test positive for 6–10 weeks.
| Consumer Profile | Urine Detection (50 ng/mL) | Blood Detection | Saliva Detection |
|---|---|---|---|
| Single use (once) | 3–7 days | 6–24 hours | 24–48 hours |
| Moderate (2–3×/week) | 7–21 days | Up to 7 days | Up to 72 hours |
| Heavy daily user (lean) | 21–45 days | Up to 14 days | Up to 72 hours |
| Heavy daily user (high body fat) | 45–90+ days | Up to 21+ days | Up to 72 hours |
| Hair follicle (any profile) | Up to 90 days regardless of use pattern | ||
Individual metabolic rate is another significant variable. People with faster overall metabolisms — influenced by genetics, thyroid function, physical activity level and age — process and excrete THC metabolites more quickly. Younger individuals tend to have faster metabolic rates and thus shorter detection windows for comparable exposure. Age-related metabolic decline can extend detection windows in older chronic users.
The relationship between physical exercise and THC detection is one of the most practically important — and often misunderstood — aspects of cannabis pharmacokinetics. Exercise induces lipolysis, the metabolic breakdown of stored triglycerides in adipose tissue to release free fatty acids for energy. Because THC is embedded in the lipid matrix of adipose cells, lipolysis can simultaneously mobilise stored THC back into the general circulation.
A landmark study published in the journal Drug and Alcohol Dependence (Fischetti et al., 2015) examined blood THC and THC-COOH concentrations in chronic cannabis users before and after a 35-minute moderate-intensity cycling session. Subjects showed statistically significant increases in blood THC concentrations after exercise compared to resting controls. The authors concluded that exercise-induced fat mobilisation releases sequestered THC back into the blood.
For drug testing purposes, this has a critical implication: engaging in vigorous exercise in the hours immediately before a blood or urine drug test can transiently elevate measurable THC-COOH concentrations, potentially pushing a marginal result above the detection threshold. The recommended approach for anyone facing a near-term drug test is to avoid strenuous exercise in the 24–48 hours preceding the test.
Conversely, long-term regular exercise supports body fat reduction. A chronically exercising individual will, over months, have reduced adipose stores and therefore a smaller THC reservoir, which translates to faster clearance timelines compared to a sedentary individual at the same consumption frequency. This is a long-term effect, not a short-term flush strategy.
Urine immunoassay (IA) tests are the most commonly used drug screening method. They detect THC-COOH glucuronide using antibody-based reactions. The federally mandated cut-off in the United States is 50 ng/mL for initial screening, with a confirmatory GC-MS cut-off of 15 ng/mL. Some employers use lower thresholds (20 ng/mL) which significantly extends the detection window.
Blood tests detect both parent THC and its metabolites in plasma. Because THC is rapidly distributed out of blood into tissues, blood tests are most useful for identifying recent (within hours) consumption. However, in heavy chronic users, low-level THC can persist in blood for 7–14 days due to continuous re-release from fat stores. Blood testing is common in impaired driving investigations but rarely used for workplace screening due to invasiveness and rapid elimination in non-heavy users.
Saliva (oral fluid) tests primarily detect parent delta-9-THC rather than metabolites. THC is deposited directly in saliva glands during and after smoking or vaping. In single-use consumers, saliva tests typically clear within 24–48 hours. In heavy daily users, studies have found positive saliva results up to 72 hours post-use. Saliva tests are favoured for roadside DUI testing due to ease of collection and short detection window correlating with recent impairment.
Hair follicle tests detect THC-COOH embedded in the hair shaft as it grows. Hair grows approximately 1 cm per month; standard tests use 3 cm of hair collected close to the scalp, covering approximately 90 days of cannabis exposure. Hair testing is highly resistant to short-term abstinence strategies. Critically, hair tests can also produce false positives from passive environmental exposure — this is a documented scientific controversy, with research showing that external cannabis smoke can deposit cannabinoids on hair strands without actual consumption.
Sweat patches are wearable devices attached to the skin for 1–2 weeks. They detect THC excreted through perspiration. Used primarily in probationary monitoring rather than one-time screening. Detection windows vary widely based on sweat rate and body fat-related release patterns.
Beyond body fat and metabolism rate, several additional factors determine how long THC remains detectable in any specific individual. Frequency and dose are the most obvious variables — daily use at high doses saturates fat stores more completely than occasional moderate use, creating a larger reservoir that takes longer to deplete.
Product potency has escalated significantly over the decades. Average THC concentrations in commercially available cannabis have risen from approximately 4% in the 1990s to 12–25% in the current market. Higher-potency products at equivalent consumption volumes deposit substantially more THC into fat stores per session. Concentrate users (wax, shatter, rosin) consuming at 70–90% THC introduce an order of magnitude more cannabinoid per session than flower consumers, which dramatically extends deposition and clearance timelines.
Hydration status affects urine test results in a specific way: it does not accelerate THC metabolism, but it does dilute the urine concentration of THC-COOH. Drinking large amounts of water before a test can temporarily reduce urine THC-COOH concentration below the 50 ng/mL cut-off. However, laboratories routinely check for sample dilution through creatinine levels and urine specific gravity. A creatinine value below 20 mg/dL flags the sample as potentially adulterated, often resulting in a required retest.
Genetic variation in CYP2C9 and CYP3A4 enzyme activity creates meaningful interindividual differences in THC metabolism rate. Poor metabolisers — individuals with naturally reduced CYP2C9 activity due to genetic polymorphisms — process THC more slowly and may show extended detection windows even with moderate consumption. This genetic factor partially explains why some individuals are "sensitive" to cannabis effects at doses others find unremarkable.
Given the science, the only reliably evidence-supported strategy for reducing detection window length is time and abstinence combined with factors that accelerate metabolism. There is no supplement, detox drink or product with clinical evidence supporting meaningful acceleration of THC clearance beyond modest diuretic effects that temporarily dilute urine concentration.
Strategies with genuine biological support include: sustained caloric deficit combined with moderate cardio exercise to reduce overall adipose volume over weeks (not hours); adequate hydration to support kidney function and urinary output; and high dietary fibre intake, which may reduce enterohepatic recirculation of THC-COOH by binding it in the gut before reabsorption.
Creatine supplementation before a urine test is sometimes used to counteract the dilution-detection mechanism by maintaining creatinine levels within the normal range even with high water intake. This approach aims to pass a diluted sample below the THC cut-off while maintaining the appearance of an undiluted specimen. This is a risk-based strategy, not a metabolism accelerant.
Yes. THC is lipophilic and accumulates in adipose tissue. Higher body fat means a larger THC reservoir and slower release, leading to longer detection windows in all test types compared to leaner individuals at the same consumption level.
Potentially yes. Exercise mobilises fat through lipolysis, which can transiently release stored THC metabolites into the bloodstream. Avoid intense exercise in the 24 hours before any drug test.
For heavy daily users, THC-COOH can remain detectable for 30–90 days after cessation at the standard 50 ng/mL urine cut-off. Body fat percentage, metabolism and product potency all influence this window significantly.
Water does not accelerate THC metabolism but can dilute urine concentration below the cut-off threshold. Labs test for creatinine and specific gravity to detect diluted samples. Diluted results often require a retest.